In the process of immunotherapy, the tumor microenvironment can be remodeled by targeting elimination of CD79A+CD24-PANCK+-BCSCs subpopulation or reversing the exhaustion of CD8+ T-cell, so as to restore the anti-tumor effect of effector T-cell. The gene discussed is CD79A; the disease is neoplasm.